U.S. Insurance Stock News

In late February 2026, Zscaler reported second-quarter results showing revenue rising to US$815.75 million while its net loss widened to US$34.31 million, and the company raised both third-quarter and full-year fiscal 2026 revenue and annual recurring revenue guidance. At the same time, Zscaler’s higher spending in a competitive market and concerns around billings, new customer growth, and integration of acquired businesses have led investors to question how durable its growth and path...

UFP Technologies (NasdaqCM:UFPT) amended its manufacturing supply agreement with Intuitive Surgical. The amendment extends the term of the partnership between the two companies. Minimum volume commitments under the agreement were increased. A new program for additional products was added to the supply arrangement. For you as an investor, this centers on UFP Technologies' role as a specialized manufacturer for the medical device sector, supplying components and solutions to a leading global...

If you are wondering whether Modine Manufacturing's current share price actually lines up with its underlying worth, you are not alone. This article is going to focus squarely on what the numbers say about value. The stock last closed at US$238.50, with returns of 7.2% over 7 days, 29.2% over 30 days, 69.4% year to date and 209.2% over 1 year, while the 3 year return is very large and the 5 year return is around 15x. Recent news around Modine Manufacturing has largely centered on its role in...

Earnings, guidance and new buyback put Expro Group Holdings (XPRO) in focus Expro Group Holdings (XPRO) is back on investors’ radar after releasing fourth quarter and full year 2025 results, setting 2026 revenue guidance, and unveiling a new US$100 million share repurchase plan. The latest numbers give you a fresh look at how the business ended 2025. The guidance and buyback outline how management is thinking about the next phase. Here is what stands out from the announcement and how you...

Harrow (NasdaqGM:HROW) has introduced a new Direct-to-Prescriber PharmaPack offering focused on post-cataract surgery care. The PharmaPack kits provide access to FDA-approved ophthalmic products and are designed to be ordered directly by eye care providers. The launch aims to reduce reliance on off-label compounded formulations and support more standardized treatment protocols. For investors following ophthalmic therapeutics, Harrow sits at the intersection of branded eye care drugs and...

In February 2026, Blue Owl Capital Inc. filed a US$615.5 million shelf registration for 50,000,000 Class A shares linked to an employee stock ownership plan, shortly after restricting withdrawals from a fund and planning to sell US$1.40 billion of assets across three funds to repay debt and return capital to investors. These moves, including the permanent removal of a quarterly withdrawal option in its smallest vehicle, highlight how Blue Owl is balancing growth ambitions with tighter...

Savara Inc. recently announced that the FDA has accepted for review its Biologics License Application for MOLBREEVI to treat autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and granted the therapy Priority Review, with a PDUFA action date set for August 22, 2026. The drug’s combination of Priority Review, Fast Track, Breakthrough Therapy, Orphan Drug, Innovation Passport, and Promising Innovative Medicine designations highlights both its potential clinical importance and the high...

If you are wondering whether Truist Financial's current share price really lines up with its underlying worth, this article will walk through the key numbers that matter most. Over the short term, the stock has seen a 1.1% decline over 7 days and a 3.6% decline over 30 days. The longer term picture shows a 14.3% return over 1 year, 26.4% over 3 years, and 5.1% over 5 years from a last close of US$49.55. Recent market attention around large US banks has kept Truist Financial in focus,...

If you are wondering whether XPeng shares are pricing in too much hope or not enough, this article walks through what the current valuation really implies for investors. The stock recently closed at US$16.99, with returns of a 3.2% decline over 7 days, a 5.5% decline over 30 days, a 16.8% decline year to date, a 16.1% decline over 1 year and an 81.3% decline over 3 years, which gives a mixed picture of sentiment and risk. Recent headlines around XPeng have focused on broad themes such as...

Vistance Networks (VISN) drew fresh attention after reporting 2025 results that included very large net income and a move from loss to profit, supported by the sale of its Connectivity and Cable Solutions segment. See our latest analysis for Vistance Networks. The share price reaction has been mixed, with a 1 day share price return of 1.59% after the results, a 90 day share price return showing an 8.51% decline, and a 1 year total shareholder return of very large magnitude that reflects how...

Recent share performance and business snapshot Booking Holdings (BKNG) has drawn investor attention after a period of mixed share performance, with gains over the past week contrasting with weaker returns over the past month and over the past 3 months. The company, headquartered in Norwalk, Connecticut, runs platforms such as Booking.com, Priceline, Agoda, KAYAK and OpenTable, generating revenue of US$26.9b and net income of US$5.4b from global travel and restaurant reservation services. See...

This article examines whether PENN Entertainment at around US$14.85 appears attractively priced or potentially a value trap, by reviewing what the available numbers indicate about the stock. The share price has moved sharply in the short term, with a 22% return over the last 7 days and 15.7% over the last 30 days. This contrasts with a 28.5% decline over 1 year and a 51% decline over 3 years. Recent headlines have focused on PENN Entertainment's position in the US gaming and entertainment...

Mosaic (MOS) is back in focus after its latest quarterly results showed a weak finish to 2025, with softness in U.S. phosphate demand, higher sulfur costs, and recent analyst downgrades pressuring sentiment. See our latest analysis for Mosaic. The earnings miss, analyst downgrades and softer U.S. phosphate demand have weighed on sentiment. The latest 1 day share price return of 1.19% and 7 day share price return of 4.25% contrast with a 90 day share price return of 12.84% and a 1 year total...

Palo Alto Investors LP opened a new position in Compass Therapeutics in the fourth quarter of 2025, acquiring 2,532,419 shares valued at about US$13.6 million, or roughly 1.89% of its assets under management. This move, alongside expectations for Compass’s bispecific antibody Tovecimig (CTX-009) in biliary tract cancer, highlights growing institutional interest in its oncology pipeline. Next, we will examine how rising institutional ownership, anchored by Palo Alto Investors’ new stake,...

NTT DOCOMO and Viavi Solutions recently completed a joint study using AI and digital twin technology to control 6G radio access networks, showing in simulations that cutting control overhead can lift system throughput by up to 20%, with results presented at Mobile World Congress Barcelona 2026. This work highlights Viavi’s growing role in AI-driven network optimization tools, positioning its test and simulation platforms at the center of future 6G architecture discussions. We’ll now examine...

If you are wondering whether Granite Construction's share price still offers value after a strong run, or if most of the upside is already reflected, this article breaks down what the current market price might be implying. The stock most recently closed at US$133.84, with a 7 day return of a 0.7% decline, a 30 day return of 10.8%, a year to date return of 12.8%, a 1 year return of 65.3%, a 3 year return that is very large, and a 5 year return that is very large. Recent price moves sit...

If you are wondering whether SPS Commerce shares are now priced attractively or still look expensive, you are not alone. This review is aimed squarely at that question. The stock most recently closed at US$58.41, with returns of 7.7% over the past week, a 34.6% decline over 30 days, a 33.6% decline year to date, and a 55.8% decline over 1 year. The 3 year and 5 year returns stand at 61.2% and 41.1% declines respectively. Recent coverage around SPS Commerce has focused on keeping investors...

Veracyte (VCYT) has drawn attention after recent share price moves, with the stock showing mixed returns across different time frames, including declines over the past month and past 3 months alongside a positive 1 year total return. See our latest analysis for Veracyte. At a share price of US$36.01, Veracyte’s recent performance reflects fading short term momentum, with a 30 day share price return of 5.44% and a 90 day share price return of a 21.99% decline, set against a 1 year total...

In late February 2026, Virtu Financial reported Q4 2025 results showing its highest quarterly adjusted net income since early 2021, supported by elevated market volatility and strong trading volumes across both Market Making and Execution Services. An interesting angle for investors is Virtu’s plan to channel this momentum into higher trading capital, upgraded infrastructure, and moves into emerging areas such as prediction markets and crypto. We’ll now explore how this stronger quarter,...

Hormel Foods stock snapshot Hormel Foods (HRL) shares trade around US$24.82, with the stock roughly flat over the past month and showing a gain in the past 3 months, set against weaker 1 year and multi year returns. See our latest analysis for Hormel Foods. The recent 1 day share price decline of 3.05% sits against a 90 day share price return of 7.49%. The 1 year total shareholder return of 12% and 5 year total shareholder return of 39.51% highlight how sentiment has weakened over time...

In February 2026, UiPath unveiled new agentic AI solutions for healthcare at the ViVE 2026 conference, targeting medical records summarization, claim denial prevention and resolution, and prior authorization, developed in collaboration with Genzeon to address data fragmentation and revenue cycle management challenges for providers and payers. By pairing agentic automation with healthcare-domain partners like Genzeon, UiPath is moving beyond generic RPA into deeply specialized,...

Zenas BioPharma has recently been highlighted for moving from a pre-revenue stage toward commercialization of its lead antibody therapy obexelimab, targeting IgG4-Related Disease, an area with no approved treatments. An interesting aspect of this story is Zenas’ reported cash position of about US$270,000,000 entering 2026, which supports its plans to expand a pipeline focused on B‑cell‑mediated autoimmune diseases while advancing obexelimab toward market. Against this backdrop, we’ll examine...

IREN (NasdaqGS:IREN) is back in focus after securing a US$9.7b, five year AI cloud services contract with Microsoft, a shift that places its high performance computing and AI infrastructure front and center for investors. See our latest analysis for IREN. Despite the Microsoft contract putting IREN firmly on the AI map, the 30 day share price return of 22.98% decline and year to date softness contrast with a very large 1 year total shareholder return. This suggests powerful but volatile...

If you are looking at Fluor and wondering whether the current share price gives you good value, you are not alone. This article focuses squarely on what you might be paying for compared to what you are getting. After closing at US$50.91, the stock has seen a 1.4% decline over the last 7 days, a 10.2% gain over 30 days, a 22.1% return year to date, and a 37.9% return over the past year, which may change how investors think about both upside and risk. Recent attention on Fluor has been driven...